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Abstract
Introduction:  Recently,  it  has  been  suggested  an  association  between  red  cell  distribution  width
(RDW) and  Crohn’s  disease  activity  index  (CDAI),  but  its  use  is  not  yet  performed  in  daily  clinical
practice.
Objectives:  To  determine  whether  RDW  can  be  used  as  a  marker  of  Crohn’s  disease  (CD)  activity.
Methods:  This  was  a  cross-sectional  study  including  patients  with  CD,  observed  consecutively
in an  outpatient  setting  between  January  1st  and  September  30th  2013.  Blood  cell  indices,
erythrocyte  sedimentation  rate  (ESR),  and  C-reactive  protein  were  measured.  CD  activity  was
determined  by  CDAI  (active  disease  if  CDAI  ≥  150).  Associations  were  analyzed  using  logistic
regression  (SPSS  version  20).
Results:  119  patients  (56%  female)  were  included  in  the  study  with  a  mean  age  of  47  years
(SD 15.2).  Twenty  patients  (17%)  had  active  disease.  The  median  RDW  was  14.0  (13--15).  There
was an  association  between  RDW  and  disease  activity  (p  =  0.044).  After  adjustment  for  age  and
gender, this  association  remained  consistent  (OR  1.20,  95%  CI  1.03--1.39,  p  =  0.016).  It  was  also
found that  the  association  between  RDW  and  disease  activity  was  independent  of  hemoglobin
and ESR  (OR  1.36,  95%  CI  1.08--1.72,  p  =  0.01)  and  of  biologic  therapy  (OR  1.19,  95%  CI  1.03--1.37,
p =  0.017).  A  RDW  cutoff  of  16%  had  a  speciﬁcity  and  negative  predictive  value  for  CDAI  ≥  150
of 88%  and  86%,  respectively.∗ Corresponding author.
E-mail address: anaoliveira.fml@gmail.com (A.M. Oliveira).
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C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Red  cell  distribution  width  as  a  marker  of  Crohn’s  disease  activity  7
Conclusion:  In  this  study,  RDW  proved  to  be  an  independent  and  relatively  speciﬁc  marker  of
CD activity.  These  results  may  contribute  to  the  implementation  of  this  simple  parameter,  in
clinical practice,  aiming  to  help  therapeutic  decisions.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
PALAVRAS-CHAVE
Doenc¸a de  Crohn;
Índices  de  Eritrócitos
A  Amplitude  de  Distribuic¸ão  dos  Glóbulos  Vermelhos  (RDW)  Pode  Ser  Considerado
Como  um  Marcador  da  Atividade  da  Doenc¸a de  Crohn?
Resumo
Introduc¸ão: Recentemente,  tem  vindo  a  ser  sugerida  uma  associac¸ão  entre  o  valor  de  RDW  e
a atividade  da  doenc¸a  de  Crohn  (DC),  mas  a  sua  utilizac¸ão  não  está  ainda  implementada  na
prática clínica  diária.
Objetivos:  Determinar  se  o  RDW  pode  ser  utilizado  como  marcador  de  atividade  da  DC.
Métodos: Estudo  transversal,  em  doentes  com  DC,  observados  consecutivamente  em  consulta
de Doenc¸a  Inﬂamatória  Intestinal,  entre  1  de  janeiro  e  30  de  setembro  de  2013.  Analisaram-se
índices do  hemograma,  proteína  C  reativa  e  velocidade  de  sedimentac¸ão.  A  gravidade  da  doenc¸a
foi avaliada  pelo  Crohn’s  disease  activity  index  (doenc¸a  ativa  se  CDAI≥150).  As  associac¸ões
foram estudadas  usando  a  regressão  logística  (SPSS  Statistics  V20).
Resultados:  Incluídos  119  doentes  (56%  do  sexo  feminino),  com  idade  média  de  47  anos  (DP  15,2
anos). Vinte  doentes  (17%)  tinham  doenc¸a  ativa.  O  valor  do  RDW  mediano  foi  14,0%  (13-15).
Veriﬁcou-se  uma  associac¸ão  entre  RDW  e  atividade  da  doenc¸a  (p  =  0,044).  Após  ajuste  para  a
idade e  o  sexo,  esta  associac¸ão  manteve-se  consistente  (OR  1,20;  95%  CI  1,03-1,39;  p  =  0,016).
Veriﬁcou-se  ainda  que  a  associac¸ão  do  valor  do  RDW  com  a  atividade  da  doenc¸a  foi  independente
do valor  da  hemoglobina  e  da  velocidade  de  sedimentac¸ão  (OR  1,36;  95%  CI  1,08-1,72;  p  =  0,01)
e da  terapêutica  biológica  (OR  1,19;  95%  CI  1,03-1,37;  p  =  0,017).  Para  um  valor  de  corte  de
RDW de  16%,  a  especiﬁcidade  e  o  valor  preditivo  negativo  de  CDAI≥  150  foram  de  88%  e  86%,
respetivamente.
Conclusão:  Neste  estudo,  o  valor  do  RDW  demonstrou  ser  um  marcador  independente  e  rel-
ativamente  especíﬁco  da  atividade  da  doenc¸a  de  Crohn.  Estes  resultados  poderão  contribuir
para a  aplicac¸ão  deste  parâmetro  simples,  na  prática  clinica  diária,  visando  auxiliar  decisões
terapêuticas.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.
Este é  um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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H1. Introduction
Crohn’s  disease  (CD)  is  a  chronic  inﬂammatory  bowel  dis-
ease  (IBD)  characterized  by  a  relapsing-remitting  clinical
behavior.1 For  this  reason,  the  assessment  of  the  severity
of  IBD  and  the  monitoring  of  disease  activity  are  important
issues.2
Currently,  endoscopy  with  biopsy  is  considered  the  gold
standard  for  the  evaluation  of  mucosal  inﬂammation.2,4
However,  endoscopy  is  invasive  and  requires  good  bowel
cleansing,  a  procedure  that  is  poorly  accepted  by  patients
and  potentially  harmful.1,2 Therefore,  CD  activity  index
(CDAI)  is  still  accepted  to  grade  CD  activity  by  inter-
national  guidelines,  namely  European  Crohn’s  and  Colitis
Organization  (ECCO).  Despite  being  based  mainly  in  clinical
parameters,  it  remains  the  principal  index  for  evaluating  CD
patients’  outcomes  in  clinical  studies.  Clinical  remission  is
accepted  as  a  CDAI  of  <150.3
t
l
sTo  improve  non-invasive  monitoring  of  CD  activity,
umerous  biomarkers  (e.g.  C-reactive  protein  (CRP),  eryth-
ocyte  sedimentation  rate  (ESR),  leukocyte  and  platelet
ounts,  albumin,  fecal  calprotectin  and  lactoferrin)5 have
een  proposed  but  few  have  proven  to  be  clinically  useful  in
BD.1,6 Nevertheless,  CRP  has  been  included  as  an  ancillary
est  to  monitor  CD  activity  by  ECCO  guidelines.3
Red  cell  distribution  width  (RDW)  is  a  quantitative  mea-
ure  of  variability  in  the  size  of  circulating  erythrocytes.7,8
t  is  routinely  measured  by  automated  hematology  ana-
yzers  and  is  usually  reported  as  a  component  of  the
omplete  blood  count  (CBC),9 thus  not  implying  additional
osts.10,11 Until  recently,  it  was  used  mainly  to  differen-
iate  iron  deﬁciency  anemia  from  thalassemia  trait.11,12
owever,  in  the  last  years,  numerous  studies  have  shown
hat  a  higher  RDW  is  associated  with  several  patho-
ogic  conditions,  including  heart  failure,9 acute  coronary
yndrome,13 atherosclerosis,14 pulmonary  impairment,15 and
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enous  thromboembolism.16 Also,  some  studies  have  sug-
ested  that  RDW  may  be  an  inﬂammatory  marker  for  IBD,
ainly  in  an  inpatient  setting.17,18
Since  RDW  is  easily  accessible  and  relatively  cheap,
nderstanding  its  prognostic  signiﬁcance  in  the  context  of
D  could  be  useful  to  optimize  clinical  decisions.  Conse-
uently,  we  hypothesized  that  RDW  may  be  a  surrogate
arker  of  CD  activity,  not  only  in  an  inpatient  setting,  but
lso  in  an  outpatient  setting.  Accordingly,  the  purpose  of  this
tudy  was,  ﬁrstly,  to  determine  whether  RDW  is  associated
ith  CDAI;  and,  secondly,  to  identify  a  possible  RDW  cutoff
ith  clinical  applicability  for  an  outpatient  setting.
. Materials and methods
.1.  Design,  setting,  and  participants
his  was  a  cross-sectional  observational  study  performed  at
he  Gastroenterology  Department  of  a  large  district  hospital
Prof.  Doutor  Fernando  Fonseca  Hospital,  Amadora,  Portu-
al).
All  CD  patients  (ascertained  by  standard  clinical,  radio-
ogical,  histological,  and  endoscopic  criteria)3 observed  in
he  IBD  outpatient  clinic  between  January  1st  and  Septem-
er  30th  2013,  with  laboratory  evaluation  up  to  2  months
efore  the  clinic  visit  were  included  in  the  study.  Patients
ith  follow-up  at  our  clinic  for  less  than  6  months,  with
aboratory  evaluation  done  more  than  2  months  before  the
linic  visit,  or  with  lack  of  information  to  assess  CDAI  were
xcluded  from  the  study.
.2.  Variables  and  primary  outcome
peciﬁc  patients’  characteristics  considered  were  the  fol-
owing:  age,  sex,  Montreal  classiﬁcation  of  CD,20 blood  cell
ndices  (RDW,  hemoglobin,  mean  cellular  volume  (MCV),
eukocyte  (WBC)  and  platelet  (PLT)  counts),  inﬂammatory
iochemical  parameters  (CRP  and  ESR),  and  medication
elated  to  CD.  In  our  Department,  CD  management  follows
CCO  guidelines.21
Primary  outcome  was  deﬁned  as  CD  activity  measured
y  CDAI.  This  index  is  a  numerical  calculation  derived  from
he  sum  of  eight  items,  each  considered  after  adjustment
ith  a  weighting  factor.  CDAI  items  include:  number  of
iquid  or  very  soft  stools,  abdominal  pain  score,  general
ellbeing,  symptoms  related  to  CD  (arthritis  or  arthral-
ia,  iritis  or  uveitis,  mucocutaneous  lesions  (e.g.  erythema
odosum,  pyoderma  gangrenosum,  aphthous  stomatitis),
nal  disease  (e.g.  ﬁssure,  ﬁstula),  external  ﬁstula  (e.g.
kin,  bladder,  vagina),  fever  >37.8 ◦C),  antidiarrheal  med-
cations  use,  abdominal  mass,  47  minus  hematocrit  (males)
r  42  minus  hematocrit  (females)  and  1  −  x  (1  −  body  weight
ivided  by  a  standard  weight).19 Patients  who  had  CDAI  ≥  150
ere  accepted  as  having  active  disease,  whilst  CDAI  <  150
eﬁned  clinical  remission.3.3.  Statistical  analysis
ontinuous  variables  were  reported  as  mean  and  standard
eviation  (SD),  if  normally  distributed,  or  median  and
t
c
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nterquartile  range  (IQR),  if  non-normally  distributed.  Cate-
orical  variables  were  reported  as  absolute  number  (n)  and
roportion  (%).
Group  comparisons  of  continuous  variables  were  per-
ormed  using  Student  t-test  or  Mann--Whitney  test,  as
ppropriate.  2 test  or  Fisher’s  exact  test  were  used  for
roup  comparisons  of  categorical  variables.
Logistic  regression  was  used  to  study  associations  with
he  primary  outcome.  Selection  of  variables  for  multivari-
te  analysis  was  based  on  clinically  relevant  knowledge  and
nivariate  comparisons  yielding  a  p  <  0.15.  A  forward  step-
ise  process  was  used  for  the  selection  of  variables  to  be
ncluded  in  ﬁnal  models.  Collinear  behavior  was  studied  and
orrected  where  applicable.  Models’  discriminative  ability
as  assessed  by  c-statistic.
A RDW  cutoff  point  with  clinical  utility  was  studied
hrough  analysis  of  the  coordinate  points  of  ROC  curve.  Sen-
itivity,  speciﬁcity,  negative  predictive  value,  and  positive
redictive  value  were  calculated  for  the  selected  cutoff
oint.
All  statistical  tests  were  two-sided  and  a p  <  0.05  was
onsidered  to  be  signiﬁcant.
Statistical  analyses  were  performed  using  SPSS®, version
0.0  (IBM,  New  York).
. Results
.1.  Baseline  characteristics
uring  the  study  period  considered,  119  patients  were
ncluded.  Females  comprised  56.3%  (n  =  67)  and  mean  age
as  47  years  (SD,  15.2  years).
According  to  the  Montreal  classiﬁcation,20 the  predomi-
ant  features  present  from  the  onset  of  disease  were  an  age
etween  17  and  40  years  (A2)  (n  =  67;  56.3%);  terminal  ileal
isease  location  (L1)  (n  =  62;  52%);  and  non-stenosing  and
on-penetrating  disease  behavior  (B1)  (n  =  66;  56%).  Perianal
isease  was  diagnosed  in  24%  (n  =  28)  of  patients.
Thiopurines  and  anti-tumor  necrosis  factor-  (anti-TNF-
)  drugs  were  in  use  by  40.3%  (n  =  48)  and  21%  (n  =  25),
espectively  (with  8.4%  (n  =  10)  patients  taking  both  drugs).
Baseline  characteristics  are  depicted  in  Table  1.
Anemia  (deﬁned  as  hemoglobin  <13  g/dL  if  male  gender;
r  hemoglobin  <12  g/dL  if  female  gender)22 was  present  in
9.4%  (n  =  35)  of  patients.
The  median  RDW  was  14.0  (13--15);  the  median  CRP  was
.0  mg/dL  (1.0--3.75)  and  mean  ESR  was  33  mm.
Concerning  CD  activity  measured  by  CDAI,  17%  (n  =  20)
f  CD  patients  had  active  disease  (CDAI  ≥  150)  whereas  83%
n  =  99)  were  in  clinical  remission.
Ten  patients  with  CDAI  ≥  150  had  CRP  ≥  1.0  mg/dL.
.2.  Univariate  analysis
n  univariate  comparisons,  RDW  (14.5  (13--17)  vs  13  (13--14);
 = 0.044),  and  anti-TNF-  drugs  (40%  vs  17%;  p =  0.044)  were
he  only  factors  associated  with  CDAI  ≥  150.Albeit  not  statistically  signiﬁcant  associated  with  CDAI,
here  was  a  trend  toward  association  between  age,  ileo-
olic  location,  perianal  disease  and  hemoglobin  value  and
ctive  disease  (Table  1).  The  other  variables  analyzed,  with
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Table  1  Overall  baseline  characteristics  and  univariate  comparisons  based  on  disease  activity  measured  by  CDAI.
n  (%),  mean  (SD),  or  median  (IQR)  CDAI  <  150  p-Value
Total  CDAI  ≥  150  (n  =  99)
(n =  119) (n  =  20)
Gender,  female  67  (56.3%)  13/20  (65%)  54/99  (54.5%)  0.39
Age, years  47  (15.2)  48  (15.3)  41  (14.2)  0.076
Age at  diagnosis,  years  36.49  (14.87)  32.3  (11.75)  37.35  (15.34)  0.168
<16 years  6  (5%)  1/20  (5%)  19/20  (95%)  1.0
17--39 67 (56.3%) 13/20  (65%) 7/20  (35%)  0.39
≥40 46 (38.7%) 6/20  (30%) 14/20  (70%) 0.38
Location, n  (%)
Ileal  62  (52%) 8/20  (40%) 54/99  (55%) 0.24
Colonic 15  (13%)  2/20  (10%)  13/99  (13%)  1
Ileocolic 38  (32%)  10/20  (50%)  28/99  (28%)  0.06
Upper gastrointestinal  tract  16  (13%)  3/20  (15%)  13/99  (13%)  0.73
Behavior
Non-stenosing,  non-penetrating 66  (55%) 13/20  (65%) 53/99  (53%) 0.35
Stenosing 28  (24%) 3/20  (15%) 25/99  (25%)  0.32
Penetrating 25  (21%) 4/20  (20%) 21/99  (21%) 1
Perianal disease 28  (24%) 8/20  (40%) 20/99  (20%) 0.06
Therapeutic
5-ASA solely  34  (28.6%)  0  34/99  (34%)  0.001
Thiopurine 48  (40.3%)  10/20  (50%)  38/99  (38%)  0.33
Anti-TNF- drugs  25  (21%)  8/20  (40%)  17/99  (17%)  0.02
Laboratory values
RDW  (n  =  119)  14.0  (13--15)  14.5  (13--17)  13  (13--14)  0.044
RDW ≥  16  (n  =  119)  18  (15.1%)  6/20  (30%)  12/99  (12%)  0.042
Hgb (g/dL)  (n  =  119)  12.96  (1.9)  12.27  (1.8)  13.11  (1.9)  0.07
Anemia (n  =  119)  35  (29.4%)  8/20  (40%)  27/99  (27%)  0.26
MCV (fL)  (n  =  117)  89.4  (7.8)  88.9  (9.5)  89.56  (7.44)  0.73
PLT (uL)  (n  =  118)  286200.85  (102750.04)  298300.00  (91909.6)  283731.63  (105087.6)  0.57
WBC (uL)  (n  =  119)  7344.66  (2849.9)  7490.35  (3636.03)  7315.2  (2685.38)  0.80
CRP (mg/dL)  (n  =  60)  1.0  (1.0--3.75)  1.0  (0--4.75)  1.0  (1.0--3.25)  0.69
ESR (mm)  (n  =  75)  33.44  (25.82)  33.92  (32.46)  33.35  (24.68)  0.95
n, frequency; SD, standard deviation; IQR, inter-quartile range; CDAI, Crohn’s disease activity index; RDW, red cell distribution width; Hgb,
hemoglobin; WBC, white blood cell count; PLT, platelet count; Anti-TNF-, anti-tumor necrosis factor-;  ESR, erythrocyte sedimentation
rate; CRP, C-reactive protein.
Anemia was deﬁned as hemoglobin <13 g/dL if male gender; or hemoglobin <12 g/dL if female gender.
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ca  special  focus  on  CRP  and  ESR,  were  not  signiﬁcantly  dif-
ferent  between  patients  with  CDAI  <  150  and  patients  with
CDAI  ≥  150.
3.3.  Multivariate  analysis
In  multivariate  analysis,  after  adjusting  for  age  and  gender,
RDW  was  associated  with  CDAI  ≥  150.  In  the  sub-population
of  patients  without  anemia,  RDW  was  also  associated  with
CDAI,  even  after  adjusting  for  age  and  gender  (Table  2).
Subsequently,  in  order  to  better  study  the  association  of
RDW  with  CDAI  ≥  150,  three  further  models  were  derived.
As  depicted  in  Table  3,  RDW  was  independently  and  consis-
tently  associated  with  CDAI  after  adjusting  for  hemoglobin
and  ESR  (Model  1),  or  ileocolic  and  perianal  disease  (Model
2),  or  anti-TNF-  therapy  (Model  3).
C
f
gFinally,  through  analysis  of  coordinate  points  of  ROC
urve,  the  cutoff  16%  was  deemed  the  best  in  prognosti-
ating  active  disease  (AUC  0.64:  95%  CI:  0.5--0.78);  inherent
ensitivity,  speciﬁcity,  negative  predictive  value,  and  posi-
ive  predictive  value  of  30%,  88%,  86%  and  33%,  respectively
Fig.  1).
.  Discussion
n  this  transversal  study,  we  found  that  an  increase  in  RDW,
 simple  parameter  that  is  reported  as  part  of  a  standard
omplete  blood  count,  was  associated  with  the  severity  of
rohn’s  disease,  assessed  by  CDAI.
This  association  remained  consistent  after  adjustment
or  clinical,  laboratory  parameters  and  therapy  (age,
ender,  disease  location,  perianal  disease,  hemoglobin  and
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Table  2  Independent  indicators  association  with  active  CD  by  multivariate  logistic  regression  analysis.
Indicator  CD  patients  CD  without  anemia
OR  (95%  CI) p-Value  OR  (95%  CI)  p-Value
RDW  1.20  (1.03--1.39)  0.016  1.59  (1.10--2.31)  0.014
Gender 1.42  (0.50--4.05)  0.510  3.06  (0.6--15.6)  0.178
Age 0.97  (0.93--1.02)  0.065  0.99  (0.94--1.04)  0.614
Multivariate logistic regression analysis for RDW, gender, age, and hemoglobin.
RDW, red cell distribution width.
Table  3  Multivariate  logistic  regression  analysis  for  the  association  between  RDW  and  CDAI.
Model  1  Model  2  Model  3
OR  (95%  CI)  p  OR  (95%  CI)  p  OR  (95%  CI)  p
RDW  1.36  (1.08--1.72) 0.01 1.18  (1.03--1.35) 0.017  1.19  (1.03--1.37)  0.017
ESR 0.99  (0.96--1.02) 0.38
Hemoglobin  1.04  (0.70--1.53) 0.85
Ileocolic  disease 2.09  (0.74--5.9) 0.165
Perianal  disease 2.27  (0.77--6.69) 0.138
Biologic  therapy  3.33  (1.13--9.78)  0.029
RDW, red cell distribution width; ESR, erythrocyte sedimentation rate OR, odds ratio; CI, conﬁdence interval.
Model 1: 2 test 9 (degrees of freedom: 3); p = 0.030; area under ROC curve: 0.73 (95% CI: 0.58, 0.89); n = 75 patients.
Model 2: 2 test 11 (degrees of freedom: 3); p = 0.012; area under ROC curve: 0.71 (95% CI: 0.58, 0.84); n = 119 patients.
Model 3: 2 test 10.5 (degrees of freedom: 2); p = 0.005; area under RO
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oigure  1  ROC  curve  for  RDW  (the  area  under  the  curve  is  0.64,
 =  0.04).  ROC,  receiver  operating  characteristic.
rythrocyte  sedimentation  rate,  and  anti-TNF-  drugs).
hese  results  are  in  line  with  previous  recent  results.9,17,18,23
The  mechanisms  that  mediate  the  relationship  between
igh  RDW  values  and  increased  CD  activity  are  still  unknown.
n  elevated  RDW  is  commonly  found  when  there  is  a
utritional  deﬁciency,  such  as  iron,  folate,  or  vitamin  B12
eﬁciency.24 Also,  conditions  that  cause  more  immature
i
i
tC curve: 0.70 (95% CI: 0.55, 0.84); n = 119 patients.
ells  to  be  released  into  the  bloodstream  (severe  blood  loss),
bnormal  hemoglobins  (e.g.  sickle  cell  anemia),  or  hemol-
sis  can  also  modify  the  shape  of  red  blood  cells,  resulting
rom  an  increased  RDW.25 Also,  it  has  been  demonstrated
hat  a  chronic  inﬂammatory  state  may  contribute  to  ineffec-
ive  erythropoiesis  causing  immature  erythrocytes  to  enter
he  circulation,  resulting  in  elevated  RDW.  Several  mecha-
isms  are  believed  to  mediate  the  relationship  between  the
hronic  inﬂammatory  state  and  ineffective  erythropoiesis
eading  to  elevated  RDW.26,27 Proinﬂammatory  cytokines  like
umor  necrosis  factor-  and  interleukin-6  may  hinder  ery-
hropoiesis  via  direct  suppression  of  erythroid  precursors,
romotion  of  apoptosis  of  precursor  cells,  enhancement  of
rythropoietin  resistance  in  the  precursor  cell  lines  and
eduction  in  bioavailability  of  iron  for  hemoglobin  synthe-
is.  Higher  oxidative  stress  may  reduce  erythrocyte  life-span
nd  thus  may  result  in  anisocytosis  due  to  an  increase  in  the
roportion  of  circulating  premature  erythrocytes.26--28
The  majority  of  patients  observed  in  the  IBD  outpatient
linic  were  in  clinical  remission,  assessed  by  CDAI.  Only  17%
ere  considered  to  have  active  disease,  despite  the  fact  that
5%  of  patients  had  complicated  CD,  deﬁned  as  stricturing
r  penetrating  behavior.
One  interesting  ﬁnding  was  that  median  CRP  value
as  1  mg/dL  both  in  patients  in  clinical  remission  and  in
atients  with  active  disease,  which  is  near  the  normal  value
<0.3  mg/dL).  As  CRP  is  considered  an  objective  marker
f  inﬂammation,5 the  low  value  may  be  explained  by  low
nﬂammatory  activity  despite  having  active  disease  accord-
ng  to  CDAI.
In  this  study,  we  analyzed  the  association  between  hema-
ological  parameters  (including  hemoglobin,  MCV,  RDW,  PLT,
tivit
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and  WBC),  CRP,  and  ESR  with  CDAI.  Through  univariate  com-
parisons,  we  demonstrated  RDW  was  the  only  laboratory
parameter  independently  associated  with  CDAI.
Multivariate  logistic  regression  analysis  revealed  that
RDW  was  associated  with  CDAI  considering  all  patients
included  in  the  study  (anemic  and  non-anemic  patients),
even  after  adjusting  for  demographic  data  (age  and  gender).
These  results  were  similar  in  the  sub-population  of  patients
without  anemia,  which  is  an  important  ﬁnding  that  is  not
completely  understood.
Song  et  al.17 reported  identical  results.  In  their  study,
they  showed  RDW  was  highly  correlated  with  disease  activity
in  non-anemic  patients  as  well  as  anemic  patients  with  IBD.
In  the  study  performed  by  Cakal  et  al.,23 it  was  also  found
that  RDW  was  signiﬁcantly  elevated  in  patients  having  active
IBD  compared  with  those  without  active  disease.
Furthermore,  hemoglobin  and  ESR,  ileocolic  and  perianal
disease,  and  anti-TNF-  therapy  did  not  considerably  mod-
ify  the  association  between  RDW  and  CDAI.  It  is  particular
relevant  the  fact  that  the  association  between  RDW  and  CD
activity  was  independent  of  anti-TNF-  drugs.  We  do  think
this  ﬁnding  may  be  due  to  a  more  severe  disease  which  is
indeed  more  difﬁcult  to  control.
These  results  are  in  line  with  the  ones  reported  by  Song
and  colleagues.17 In  multivariate  analysis,  after  adjusting
for  patient  demographics  and  hematologic  parameters,  the
authors  showed  RDW  was  associated  with  CDAI  ≥  150.
Finally,  this  study  revealed  RDW  cutoff  of  16%  had  high
speciﬁcity  and  negative  predictive  value  for  determining  the
disease  activity  in  CD  patients,  albeit  with  a  low  sensitivity.
The  low  positive  predictive  value  may  be  due  to  the  low
prevalence  of  primary  outcome.
In  the  study  performed  by  Yesil  et  al.,18 a  RDW  cutoff
of  14.7  had  a  sensitivity  of  45%  and  a  speciﬁcity  of  96%  in
detecting  active  CD.  However,  in  the  Cakal  et  al.’s23 study
a  RDW  cutoff  of  14.1  showed  78%  sensitivity  and  only  63%
speciﬁcity  to  detect  active  CD.
4.1.  Strengths  and  limitations
This  study  has  some  limitations  that  may  be  referred.
First,  this  is  an  observational  study  performed  in  one
hospital  only.  For  this  reason,  it  is  prone  to  selection  bias
and  limited  generalization.  Second,  the  size  of  our  popula-
tion  with  active  disease  was  small  due  to  the  fact  that  all
patients  included  were  in  outpatient  setting.  Future  stud-
ies  with  a  larger  population  of  active  CD  patients  will  allow
to  accurately  identify  the  degree  of  RDW  increase  which
reveals  active  disease.  Third,  iron  status  was  not  determined
(which,  as  discussed  above,  may  inﬂuence  RDW  values).
Strengths  of  this  study  include  the  fact  that  all  patients
included  were  in  outpatient  setting  and  association  between
RDW  and  CDAI  was  adjusted  for  clinical  and  laboratory
parameters  that  are  relevant  in  daily  clinical  practice.
Second,  RDW  is  routinely  measured  by  automated  hema-
tology  analysers  and  is  reported  as  a  component  of  the
complete  blood.  Thus,  testing  RDW  is  easy  to  perform,
affordable  and  does  not  require  any  additional  costs.If  in  future  of  large  prospective  studies,  RDW  is  conﬁrmed
to  be  an  accurate  parameter  for  disease  activity  monitor-
ing,  this  could  impact  positively  outpatient  IBP  patients’
surveillance  and  decision  making.
1y  11
.  Conclusion
n  conclusion,  in  this  study  we  demonstrated  RDW  was  asso-
iated  with  the  severity  of  Crohn’s  disease,  assessed  by
rohn’s  disease  activity  index.  The  RDW  cutoff  16%  showed
ossible  clinical  applicability.
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